December 16, 2020: What can be done to improve the quality of the data prior to FDA making a decision about whether or not to approve a new indication for spironolactone?
Read More »Tag: heart failure
NCHR Statement about Entresto at FDA Cardiovascular and Renal Drugs Advisory Committee Meeting
December 15, 2020. FDA should not approve this new indication until an adequate number of Black patients have been studied and the results are conclusive for all patients.
Read More »NCHR Testimony at the FDA on Optimizer for Heart Failure
December 4, 2018. We all want to help these patients, but new treatments need to provide a real benefit. The questions that we need to answer are does this device help patients and should patients continue to have the option of receiving an experimental treatment as part of a clinical trial, or should they pay for an experimental treatment that has been described as a breakthrough?
Read More »